Alterations in gene expression in MEN1-associated insulinoma development

Pancreas

Volumn 39, Issue 8, 2010, Pages 1140-1146

  Serewko Auret, Magdalena M ^a   Mould, Arne W ^a   Loffler, Kelly A ^a   Duncan, Russell ^a   Kay, Graham F ^a   Hayward, Nicholas K ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

endocrine; gene expression; insulinoma; MEN1; multiple endocrine neoplasia type 1; pancreas

Indexed keywords

CALGRANULIN A; TRANSCRIPTION FACTOR GATA 6;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER GROWTH; COBLL1 GENE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; INSULINOMA; LMO2 GENE; MEOX1 GENE; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PANCREAS ISLET; PPIA GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TSPAN8 GENE;

ANIMALS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CALGRANULIN A; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GATA6 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; HUMANS; INSULINOMA; ISLETS OF LANGERHANS; MALE; MEMBRANE GLYCOPROTEINS; METALLOPROTEINS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78049257747     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181dc67fc     Document Type: Article

References (46)

1. Larsson C, Nordenskjold M. Multiple endocrine neoplasia. Cancer Surv. 1990;9(4):703-723.
2. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404- 407.
3. Lemmens I, Van de Ven WJ, Kas K, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet. 1997;6(7):1177-1183.
4. Guru SC, Goldsmith PK, Burns AL, et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A. 1998;95(4):1630-1634.
5. Huang SC, Zhuang Z, Weil RJ, et al. Nuclear/cytoplasmic localization of the multiple endocrine neoplasia type 1 gene product, menin. Lab Invest. 1999;79(3):301-310.
6. Kaji H, Canaff L, Goltzman D, et al. Cell cycle regulation of menin expression. Cancer Res. 1999;59(20):5097-5101.
7. Yokoyama A, Somervaille TC, Smith KS, et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207-218.
8. Bergman L, Boothroyd C, Palmer J, et al. Identification of somatic mutations of the MEN1 gene in sporadic endocrine tumours. Br J Cancer. 2000;83(8):1003-1008.
9. Mould AW, Duncan R, Serewko-Auret M, et al. Global expression profiling of murine MEN1-associated tumors reveals a regulatory role for menin in transcription, cell cycle and chromatin remodelling. Int J Cancer. 2007;121(4):776-783.
10. Scacheri PC, Davis S, Odom DT, et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet. 2006;2(4):e51.
11. Biondi C, Gartside M, Tonks I, et al. Targeting and conditional inactivation of the murine Men1 locus using the Cre recombinase: loxP system. Genesis. 2002;32(2):150-151.
12. Biondi CA, Gartside MG, Waring P, et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol. 2004;24(8):3125-3131.
13. Imbeaud S, Graudens E, Boulanger V, et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res. 2005; 33(6):e56.
14. Kent WJ. BLATVthe BLAST-like alignment tool. Genome Res. 2002;12(4):656-664.
15. Loffler KA, Biondi CA, Gartside M, et al. Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. Int J Cancer. 2007;120(2):259-267.
16. Matsui H, Takahashi T, Raghow R. The mechanism of biogenesis and potential function of the two alternatively spliced mRNAs encoded by the murine Msx3 gene. Mol Cell Biochem. 2004;267(1-2):1-11.
17. Ketola I, Otonkoski T, Pulkkinen MA, et al. Transcription factor GATA-6 is expressed in the endocrine and GATA-4 in the exocrine pancreas. Mol Cell Endocrinol. 2004;226(1-2):51-57.
18. Decker K, Goldman DC, Grasch CL, et al. Gata6 is an important regulator of mouse pancreas development. Dev Biol. 2006;298(2):415-429.
19. Mould AW, Duncan R, Serewko-Auret M, et al. Global expression profiling of sex cord stromal tumors from Men1 heterozygous mice identifies altered TGF-beta signaling, decreased Gata6 and increased Csf1r expression. Int J Cancer. 2009;124(5):1122-1132.
20. Afouda BA, Ciau-Uitz A, Patient R. GATA4, 5 and 6 mediate TGFbeta maintenance of endodermal gene expression in Xenopus embryos. Development. 2005;132(4):763-774.
21. Johnsen IK, Kappler R, Auernhammer CJ, et al. Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. Cancer Res. 2009;69(14):5784-5792.
22. Peterkin T, Gibson A, Patient R. GATA-6 maintains BMP-4 and Nkx2 expression during cardiomyocyte precursor maturation. EMBO J. 2003;22(16):4260-4273.
23. Takayasu H, Nakazawa N, Montedonico S, et al. Down-regulation of Wnt signal pathway in nitrofen-induced hypoplastic lung. J Pediatr Surg. 2007;42(2):426-430.
24. Zhang Y, Goss AM, Cohen ED, et al. A Gata6-Wnt pathway required for epithelial stem cell development and airway regeneration. Nat Genet. 2008;40(7):862-870.
25. Hendy GN, Kaji H, Sowa H, et al. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res. 2005;37(6):375-379.
26. Sowa H, Kaji H, Hendy GN, et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem. 2004;279(39):40267-40275.
27. Chen G, A J, Wang M, et al. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol Cancer Res. 2008;6(12): 1894-1907.
28. Zhou Z, Ran YL, Hu H, et al. TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin Exp Metastasis. 2008;25(5):537-548.
29. Kuhn S, Koch M, Nubel T, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res. 2007;5(6):553-567.
30. Kanetaka K, Sakamoto M, Yamamoto Y, et al. Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol. 2001;35(5):637-642.
31. Gesierich S, Paret C, Hildebrand D, et al. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res. 2005;11(8):2840-2852.
32. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9(1):40-55.
33. Le Naour F, Andre M, Greco C, et al. Profiling of the tetraspanin web of human colon cancer cells.Mol Cell Proteomics. 2006;5(5):845-857.
34. Cross SS, Hamdy FC, Deloulme JC, et al. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005;46(3): 256-269.
35. Yao R, Lopez-Beltran A, Maclennan GT, et al. Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res. 2007;27(5A):3051-3058.
36. Yao R, Davidson DD, Lopez-Beltran A, et al. The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol. 2007;22(9):1025-1032.
37. Stulik J, Osterreicher J, Koupilova K, et al. The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8 positive cells underlie and invade tumor mass. Electrophoresis. 1999;20(4-5):1047-1054.
38. Hermani A, De Servi B, Medunjanin S, et al. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res. 2006;312(2):184-197.
39. Heppner C, Bilimoria KY, Agarwal SK, et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaBYmediated transactivation. Oncogene. 2001;20(36): 4917-4925.
40. Warren AJ, Colledge WH, Carlton MB, et al. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 1994;78(1):45-57.
41. Zhu H, Traver D, Davidson AJ, et al. Regulation of the lmo2 promoter during hematopoietic and vascular development in zebrafish. Dev Biol. 2005;281(2):256-269.
42. Ma S, Guan XY, Beh PS, et al. The significance of LMO2 expression in the progression of prostate cancer. J Pathol. 2007;211(3):278-285.
43. Fisch P, Boehm T, Lavenir I, et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene. 1992;7(12):2389-2397.
44. Neale GA, Rehg JE, Goorha RM. Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice. Leukemia. 1997;11(suppl 3):289-290.
45. Yamada Y, Warren AJ, Dobson C, et al. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A. 1998;95(7):3890-3895.
46. Yamada Y, Pannell R, Forster A, et al. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. Oncogene. 2002;21(9):1309-1315.